Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Generalized Myasthenia Gravis

In brief

This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics (PD), immunogenicity, and efficacy of subcutaneous (SC) ALXN1830 in adults with generalized myasthenia gravis (gMG).

Key facts

Study ID

NCT04982289

Run by

Alexion Pharmaceuticals, Inc.

People needed

0

Starts

2022-01-01

Expected to finish

2024-01-31

Last updated by the study team

2022-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Clinical Study Site — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.